Working… Menu

A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03277261
Recruitment Status : Completed
First Posted : September 11, 2017
Last Update Posted : May 20, 2021
Information provided by (Responsible Party):
TG Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 23, 2020
Actual Study Completion Date : November 6, 2020
Certification/Extension First Submitted : May 11, 2021